Buffett gets in on Biogen

Looks like Warren Buffett’s betting on Alzheimer's and aducanumab: Berkshire Hathaway recently bought 648,000 shares of Biogen, according to a regulatory filing. The billionaire has dabbled — just a touch — in biopharma, with Teva being one such stock in his portfolio. 

But this foray into biotech is still uncommon for Buffett. It’s a small wager for Berkshire Hathaway — much less than 1% of Biogen shares — comparable to a non-mogul betting like $1 on the Super Bowl. What’s the point?